Key Takeaways:
Key Takeaways:
AstraZeneca Plc and Keymed Biosciences Inc. said their jointly developed antibody-drug conjugate CMG901 (sonesitatug vedotin, AZD0901) met its primary endpoint in a global Phase III trial for advanced gastric cancer, with the British drugmaker projecting peak sales of as much as $5 billion.
The CLARITY-Gastric01 study showed a statistically significant and clinically meaningful improvement in overall survival compared with investigator's choice of chemotherapy among second-line and later-line patients with CLDN18.2-positive advanced gastric cancer, the companies said in a statement. The trial enrolled patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, requiring at least 25% of tumor cells expressing CLDN18.2.
"These results confirm the potential of CMG901 as a targeted therapy for patients with limited treatment options," Pascal Soriot, chief executive officer of AstraZeneca, said on a call with reporters Monday. The company expects to file for regulatory approvals based on the data.
The positive readout comes as AstraZeneca reported second-quarter earnings that beat analyst estimates, with core earnings per share of $2.63 topping the $2.48 consensus. The company reiterated its full-year 2026 guidance and its ambition to reach $80 billion in annual revenue by 2030. AstraZeneca shares rose 1.5% in London trading.
CMG901 is a CLDN18.2-targeted antibody-drug conjugate, a class of cancer therapies that deliver a toxic payload directly to tumor cells. The drug did not show a statistically significant change on progression-free survival, though the overall survival benefit supports regulatory submissions. AstraZeneca's $3 billion to $5 billion peak sales forecast underscores the commercial opportunity in gastric cancer, a disease with high unmet need where CLDN18.2 is emerging as a key biomarker.
The results strengthen AstraZeneca's oncology pipeline as it prepares for more than 20 major clinical readouts over the next 18 months. For Keymed Bio, the data increases the probability of approval for its first wholly owned asset. Investors will watch for regulatory filing timelines and potential competition from other CLDN18.2-targeted therapies in development.
This article is for informational purposes only and does not constitute investment advice.
